Last updated on November 21, 2025
Yes, but only under strict conditions. Since July 2023, authorised psychiatrists in Australia can prescribe psilocybin for treatment-resistant depression through the Therapeutic Goods Administration’s Authorised Prescriber scheme, ensuring rigorous safety and ethical standards.
The Legal Framework
Australia’s decision to allow psilocybin for therapeutic use represents a major regulatory milestone. Psilocybin, the psychoactive compound found in certain species of mushrooms, was historically classified as a Schedule 9 Prohibited Substance, meaning it could only be used for research purposes. However, following extensive scientific review and public consultation, the Therapeutic Goods Administration (TGA) reclassified psilocybin as a Schedule 8 Controlled Drug for very specific medical contexts starting July 1, 2023.
This reclassification does not mean psilocybin is freely available. It is permitted only for treatment-resistant depression (TRD), a severe condition where patients have not responded to conventional therapies such as antidepressants or psychotherapy. Prescribing rights are limited to psychiatrists who have obtained approval under the Authorised Prescriber scheme, which requires endorsement from a Human Research Ethics Committee and submission of a detailed clinical protocol to the TGA.
Conditions for Prescribing
The process for prescribing psilocybin is highly regulated. Psychiatrists must demonstrate specialized training in psychedelic-assisted therapy and provide evidence of clinical governance. Treatment sessions must occur in controlled environments such as hospitals or accredited clinics, with continuous monitoring by qualified professionals. Patients cannot take psilocybin home; all doses are administered under supervision to ensure safety and prevent misuse.
The TGA also mandates strict record-keeping and reporting requirements. Prescribers must document patient outcomes, adverse events, and compliance with ethical standards. These measures aim to balance innovation with patient protection, given the experimental nature of psychedelic therapy.
About Psilocybin as a Product
Psilocybin is a naturally occurring compound found in certain mushrooms, often referred to as “magic mushrooms.” In therapeutic settings, psilocybin is synthesized or extracted under pharmaceutical-grade conditions to ensure purity and consistency. Unlike recreational use, medical psilocybin is administered in precise doses tailored to the patient’s needs.
The compound works by interacting with serotonin receptors in the brain, producing profound changes in perception, mood, and cognition. Clinical studies suggest that psilocybin can “reset” neural pathways associated with depression, offering relief for patients who have exhausted other options. However, these effects require careful psychological support, as the experience can be intense and emotionally challenging.
Currently, there are no TGA-approved psilocybin products listed on the Australian Register of Therapeutic Goods. This means psychiatrists must source unapproved medicines through regulated pathways, adding complexity to access. These products are typically imported under strict controls, and their use is monitored closely by regulatory authorities.
Safety and Ethical Considerations
Psilocybin therapy is not a standalone treatment. It is delivered as part of a structured program that includes preparatory sessions, guided administration, and integration therapy afterward. Patients are screened for contraindications such as psychosis or cardiovascular issues, as these conditions can increase risks during psychedelic experiences.
The therapy environment is designed to be calm and supportive, often involving comfortable rooms, soothing music, and continuous observation. This controlled setting minimizes anxiety and ensures that patients can process the experience safely. Ethical guidelines emphasize informed consent, transparency about potential risks, and respect for patient autonomy.
Regulatory Oversight
The TGA’s decision reflects a cautious but progressive approach. While psilocybin remains prohibited for general use, its medical application is tightly regulated to prevent misuse and safeguard public health. State and territory laws also apply, meaning psychiatrists must comply with local requirements for handling Schedule 8 substances, including secure storage and reporting.
Failure to adhere to these regulations can result in severe penalties, including loss of prescribing rights and criminal charges. This underscores the importance of compliance for healthcare providers entering this emerging field.
Looking Ahead
Australia’s move has sparked global interest, positioning the country as a leader in psychedelic medicine. Ongoing research will determine whether psilocybin becomes a mainstream treatment for depression or remains a niche option for severe cases. For now, access is limited, costly, and highly controlled—but for patients with treatment-resistant depression, it offers a new ray of hope.
See more about Australia
Sources
Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists
https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists
3 Feb 2023
MDMA and psilocybine hub – Therapeutic Goods Administration (TGA)
https://www.tga.gov.au/products/unapproved-therapeutic-goods/mdma-and-psilocybine/access-pathways/mdma-and-psilocybine-hub
11 Sep 2024